SoftOx Solutions AS (SoftOx), a clinical-stage biopharmaceutical company based
in Norway, announces that it has published its Annual Report for 2021. The Board
of Directors has approved the 2021 annual financial statements prepared in
accordance with the Norwegian Accounting Act and accounting standards and
practises generally accepted in Norway. The financial statements are in
accordance with the Q4 reporting published on 16th February 2022. 

"We look back on 2021 as the year of the formal validation of our technology in
clinical trials and in the healthcare sector. This is the beginning of a
breakthrough for the prevention and treatment  of infections ", says CEO Geir
Almås of SoftOx. "2021's successes far outweighed the challenges, and we are
closer than ever to achieving our goals of sharing a new class of
antimicrobials. The global attention on viruses and antimicrobial resistance
confirms the need for what we have been working on for years - a new solution to
fight infections." 


Attached to this notice are the Company's annual accounts for the financial year
2021, including the financial statements, annual report for the financial year
2021, and auditor's report. 

These documents are also available at the Company's website, 
https://soft-ox.com/press-releases-updates/. 
  
For further information, please contact: 
Geir Almås, CEO of SoftOx Solutions AS, or 
Kristine Rød, CFO at SoftOx Solutions AS 
Mail: ir@soft-ox.com 
Phone: Front Desk: (+47) 948-59-599 
  
About SoftOx Solutions AS 
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
medtech/biotech company based in Oslo with the aim of helping to combat major
threats to human health, namely the emergence of antimicrobial resistance (AMR),
biofilm infections in chronic wounds and the spread of viruses. For more
information on SoftOx, visit www.soft-ox.com